News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
257,497 Results
Type
Article (13417)
Company Profile (73)
Press Release (244007)
Section
Business (87642)
Career Advice (455)
Deals (15317)
Drug Delivery (59)
Drug Development (36419)
Employer Resources (49)
FDA (6205)
Job Trends (6176)
News (149465)
Policy (13984)
Tag
Academia (436)
Africa (311)
Allergies (11)
Alliances (22997)
ALS (10)
Alzheimer's disease (313)
Antibody-drug conjugate (ADC) (18)
Approvals (6190)
Arizona (29)
Artificial intelligence (35)
Asia (19534)
Australia (2518)
Bankruptcy (143)
Best Places to Work (4154)
Biosimilars (24)
C2C Services and Suppliers (10617)
California (294)
Canada (297)
Cancer (56)
Cardiovascular disease (11)
Career advice (398)
Cell therapy (17)
China (21)
Clinical research (29852)
Collaboration (24)
COVID-19 (729)
Cystic fibrosis (20)
Delaware (11)
Diabetes (10)
Diagnostics (1181)
Diversity, equity & inclusion (13)
Drug pricing (38)
Earnings (30826)
Employer resources (43)
Europe (38199)
Events (36047)
Executive appointments (14)
FDA (6221)
Florida (23)
Funding (13)
Gene editing (12)
Gene therapy (28)
GLP-1 (242)
Government (1242)
Healthcare (3489)
Hotbed/Location (177995)
Illinois (50)
Indiana (42)
Infectious disease (731)
Inflammatory bowel disease (39)
Interviews (57)
IPO (5756)
IRA (14)
Job creations (2047)
Job search strategy (371)
Kansas (45)
Layoffs (159)
Legal (3398)
Liver cancer (16)
Lung cancer (13)
Management (16)
Manufacturing (27)
Maryland (47)
Massachusetts (198)
Medical device (1249)
Medtech (1250)
Mergers & acquisitions (9439)
Metabolic disorders (65)
Neuroscience (346)
New Jersey (33)
New York (27)
NextGen Class of 2024 (1574)
Non-profit (588)
North Carolina (68)
Obesity (42)
Opinion (102)
Patents (21)
Pennsylvania (14)
People (28097)
Phase I (7777)
Phase II (12627)
Phase III (11335)
Podcasts (32)
Policy (23)
Postmarket research (1398)
Preclinical (3117)
Rare diseases (29)
Real estate (2626)
Recruiting (17)
Regulatory (9628)
Reports (12)
Research institute (562)
Resumes & cover letters (55)
South America (496)
Startups (1623)
Texas (27)
United States (969)
Vaccines (77)
Washington State (30)
Weight loss (38)
Date
Today (24)
Last 7 days (181)
Last 30 days (726)
Last 365 days (13698)
2024 (7744)
2023 (14247)
2022 (19567)
2021 (20078)
2020 (19043)
2019 (14906)
2018 (11725)
2017 (13892)
2016 (13133)
2015 (15473)
2014 (12425)
2013 (10598)
2012 (11396)
2011 (11925)
2010 (10888)
257,497 Results for "acadia pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Acadia Pharmaceuticals to Participate at Upcoming May 2024 Investor Conferences
Acadia Pharmaceuticals Inc. announced that it will participate at three upcoming investor conferences.
May 9, 2024
·
1 min read
Biotech Beach
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 17, 2024
Acadia Pharmaceuticals Inc. announced that on May 15, 2024, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units to twenty-two new employees under Acadia’s 2023 Inducement Plan.
May 17, 2024
·
2 min read
Business
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.
May 8, 2024
·
11 min read
Biotech Beach
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 19, 2024
Acadia Pharmaceuticals Inc. announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units to six new employees under Acadia’s 2023 Inducement Plan.
April 19, 2024
·
2 min read
Business
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets.
April 24, 2024
·
1 min read
Biotech Beach
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado.
June 18, 2024
·
10 min read
Biotech Beach
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time.
March 13, 2024
·
1 min read
Biotech Beach
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time.
April 1, 2024
·
1 min read
Deals
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 15, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units (“RSUs”) to three new employees under Acadia’s 2023 Inducement Plan.
March 15, 2024
·
2 min read
Biotech Beach
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder.
April 22, 2024
·
6 min read
1 of 25,750
Next
